Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

Immunotherapies have yet to demonstrate significant efficacy in the treatment of hormone receptor–positive (HR(+)) breast cancer. Given that endocrine therapy (ET) is the primary approach for treating HR(+) breast cancer, we investigated the effects of ET on the tumor immune microenvironment (TME) i...

Descripción completa

Detalles Bibliográficos
Autores principales: Hermida-Prado, Francisco, Xie, Yingtian, Sherman, Shira, Nagy, Zsuzsanna, Russo, Douglas, Akhshi, Tara, Chu, Zhengtao, Feit, Avery, Campisi, Marco, Chen, Minyue, Nardone, Agostina, Guarducci, Cristina, Lim, Klothilda, Font-Tello, Alba, Lee, Irene, García-Pedrero, Juana, Cañadas, Israel, Agudo, Judith, Huang, Ying, Sella, Tal, Jin, Qingchun, Tayob, Nabihah, Mittendorf, Elizabeth A., Tolaney, Sara M., Qiu, Xintao, Long, Henry, Symmans, William F., Lin, Jia-Ren, Santagata, Sandro, Bedrosian, Isabelle, Yardley, Denise A., Mayer, Ingrid A., Richardson, Edward T., Oliveira, Giacomo, Wu, Catherine J., Schuster, Eugene F., Dowsett, Mitch, Welm, Alana L., Barbie, David, Metzger, Otto, Jeselsohn, Rinath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Translational Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543960/
https://www.ncbi.nlm.nih.gov/pubmed/37450351
http://dx.doi.org/10.1158/0008-5472.CAN-23-1711

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543960/
https://www.ncbi.nlm.nih.gov/pubmed/37450351
http://dx.doi.org/10.1158/0008-5472.CAN-23-1711

Ejemplares similares